Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
5.78
-0.28 (-4.54%)
Sep 11, 2026, 4:08 PM HKT
HKG:1167 Revenue
Jacobio Pharmaceuticals Group had revenue of 730.87M CNY in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 738.73M, up 266.85% year-over-year. In the year 2025, Jacobio Pharmaceuticals Group had annual revenue of 53.53M, down -65.62%.
Revenue (ttm)
738.73M CNY
Revenue Growth
+266.85%
P/S Ratio
5.31
Revenue / Employee
3.57M CNY
Employees
207
Market Cap
4.53B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.53M | -102.18M | -65.62% |
| Dec 31, 2024 | 155.71M | 92.19M | 145.13% |
| Dec 31, 2023 | 63.52M | -32.23M | -33.66% |
| Dec 31, 2022 | 95.75M | -57.06M | -37.34% |
| Dec 31, 2021 | 152.81M | -333.48M | -68.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Shanghai Haohai Biological Technology | 2.68B |
| Qyuns Therapeutics | 1.18B |
| Ocumension Therapeutics | 1.08B |
| Mirxes Holding Company | 166.32M |
| Abbisko Cayman | 112.29M |
| TransThera Sciences (Nanjing) | 40.93M |
| Shanghai Bao Pharmaceuticals | 19.67M |
Jacobio Pharmaceuticals Group News
- 16 days ago - Jacobio Turns A Profit In Q2 On Higher Revenue - Nasdaq
- 18 days ago - Jacobio Pharmaceuticals Group Earnings release: H1 2026 - Filings
- 6 months ago - Jacobio Pharmaceuticals Group Earnings release: H2 2025 - Filings
- 6 months ago - Jacobio Pharmaceuticals Group Annual report: H2 2025 - Filings
- 8 months ago - Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 - PRNewsWire
- 11 months ago - Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline - PRNewsWire
- 1 year ago - Jacobio Pharma Announces 2025 Interim Results - PRNewsWire
- 1 year ago - Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted - PRNewsWire